Gain Insights from our 2021 Panelists

  • Daniel S.Chen MD, PhD – IGM Biosciences
  • Ron Akehurst DSc, MFPH – BresMed
  • Kenneth C. Anderson MD – Dana-Farber Cancer Institute
  • Robert Ang MBBS, MBA  – Vor Bio Pharm
  • Peter Bach MD, MAPP -Memorial Sloan Kettering Cancer Center
  • Keith Bahjat – Astellas
  • Debora Barton MD – Carisma Therapeutics Inc.
  • Jacob Becraft PhD – Strand Therapeutics
  • Sharon Benzeno PhD, MBA – Adaptive Biotechnologies Corp.
  • Philip Bland-Ward PhD -Crescendo Biologics Ltd
  • Greg Block PhD – Notch Therapeutics
  • Jeffrey M. Bockman PhD – Cello Health BioConsulting
  • Frank Borriello MD, PhD – Alloplex Biotherapeutics
  • Nicholas A. Boyle PhD, MBA – Abintus Bio
  • Neil Brewis PhD – F-star Biotech
  • Jay Campbell – Clinical Accelerator and Venture Fund, Cancer Research Institute
  • Margarita Chavez JD – AbbVie Ventures (tentative)
  • Lung-I Cheng PhD
  • Sabine Chlosta MD – Triumvera
  • Michael Curran PhD – The University of Texas MD Anderson Cancer Center
  • John Delyani PhD, MBA – Tminuty Therapeutics Inc
  • John DeYoung – Pfizer Inc.
  • Kapil Dhingra MB,BS – KAPital Consulting LLC
  • Eliot Forster BSc, PhD, MBA, FRSA – F-star Biotech
  • Björn Frendéus – BioInvent International
  • Jeremy Goldberg – Arsenal Capital Partners
  • Julie R Gralow MD, FACP, FASCO
  • Lee Greenberger MD, PhD – Leukemia & Lymphoma Society
  • Valerie Odegard PhD – Silverback Therapeutics
  • Ralph E. Parchment PhD – NCI
  • Rachel Haurwitz PhD – Caribou Biosciences, Inc.
  • Sandy Hayes PhD – Adicet Therapeutics
  • Ajla Hrle PhD – Immatics
  • David Hyman MD – Loxo
    Oncology at Lilly
  • Maha Katabi PhD, CFA – Sofinnova Investments
  • Jeff Kmetz – Ascentage Pharma
  • Michael J. Kolodzie MD – ADVI Health
  • Mythili Koneru MD, PhD – Marker Therapeutics
  • Nora “Ku” MD – Loxo Oncology at Lilly
  • Lawrence Lamb PhD – in8bio
  • Kaouthar Lbiati, MD – Cytovia Therapeutics
  • James T. Lee PhD – Cello Health BioConsulting
  • Laurent Levy PhD – Nanobiotix
  • Brian Leyland-Jones MB BS, PhD – National Foundation for Cancer Research
  • Philippe Lopes-Fernandes – Ipsen
  • Jean-François
  • Martini PhD, MSc – Pfizer Inc
  • Stephan Matthias MD PhD – Fred Hutchinson Cancer Center
  • Jan ter Meulen MD, PhD – Obsidian Therapeutics, Inc.
  • Christopher Mortko – Merck & Co., Inc
  • Carolyn Ng – Vertex Ventures
  • Kimberly Noonan – WindMIL
  • Valerie Odegard PhD – Silverback Therapeutics
  • Ralph E. Parchment PhD – NCI
  • Mark Pegram MD – Stanford Comprehensive Cancer Institute, Stanford University
  • Daniel Pollyea MD, MS – University of Colorado School of Medicine
  • Steven C Quay, MD, PhD – Atossa Therapeutics
  • Paul D. Rennert – Aleta Biotherapeutics
  • Katy Rezvani MD, PhD – MD Anderson Cancer Center
  • Michael C. Rice MS, MBA – Cello Health BioConsulting
  • Fernando J Salles PhD – I-Mab Biopharma
  • Leonard Saltz MD – Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center
  • Joel S Sandler PhD – Cello Health BioConsulting
  • Peter Sandor MD, MBA – Astellas
  • Richard Schilsky MD, FACP, FSCT, FASCO – University of Chicago
  • Emmett Schmidt MD, PhD – Merck and Co.
  • Arndt Schottelius MD, PhD – Affimed
  • Taylor Schreiber MD, PhD – Shattuck Labs, Inc.
  • Thomas Schuetz MD, PhD – Compass Therapeutics
  • Dan Shoemaker PhD – Fate Theraputics
  • Yaping Shou MD, PhD – Lilly Asia Ventures
  • Mark Simon – Torreya
  • Deepa Talpade PhD – Bayer
  • Alan Trounson MSc, PhD – Cartherics
  • Anna Turetsky – Venture Investments, The Mark Foundation
  • Peter Van Vlasselaer PhD – Amphivena Therapeutics Inc
  • Guillaume Vignon PhD – BeiGene
  • Sarah Warren PhD – Nanostring Technology
  • Paul Workman – The Institute of Cancer Research
  • Paul Wotton PhD – Obsidian Therapeutics, Inc.
  • Ed Zhang – Hillhouse Capital Management
  • Mai-Britt Zocca PhD – IO Biotech